Department of Neurology, University of Rochester, Rochester, New York, USA.
Center for Health and Technology, Rochester, New York, USA.
Muscle Nerve. 2021 Jun;63(6):837-844. doi: 10.1002/mus.27223. Epub 2021 Mar 24.
The Spinal Muscular Atrophy Health Index (SMA-HI) is a multifaceted, disease-specific, patient-reported outcome to measure an SMA patient's perception of their disease burden. In preparation for upcoming therapeutic trials, we examine the validity, reliability, and usability of the SMA-HI in adults, teenagers, and children with SMA.
Using data from a cross-sectional study of 359 international adult patients with SMA, we identified the most relevant symptoms to include in the SMA-HI. We utilized factor analysis, patient interviews with adults and minors (age 8-15 years), known-group validity testing, and test-retest reliability assessments to evaluate and refine the SMA-HI.
The SMA-HI measures overall disease burden and 15 areas of SMA health. Fifteen adult patients and five patients, age 8 to 15 years, participated in semistructured qualitative interviews and found the SMA-HI to be comprehensive, easily completed, and to have clear meaning. The final SMA-HI and its subscales demonstrated good internal consistency (Cronbach α = 0.77-0.96), high test-retest reliability (intraclass correlation coefficient = 0.60-0.96), and an ability to differentiate between SMA groups with different disease severities affecting areas such as employment and ambulation (P < .0001 for both).
This research provides evidence that the SMA-HI is a valid, relevant, and reliable outcome measure to assess multifaceted patient-reported disease burden in older children, teenagers, and adults with SMA. The SMA-HI provides an opportunity for researchers and clinicians to measure a SMA patient's perception of their health and determine relevant changes in response to therapeutic intervention or disease progression.
脊髓性肌萎缩症健康指数(SMA-HI)是一种多方面的、针对特定疾病的、患者报告的结果,用于衡量 SMA 患者对其疾病负担的感知。为了为即将进行的治疗试验做准备,我们检查了 SMA-HI 在成人、青少年和儿童 SMA 患者中的有效性、可靠性和可用性。
使用来自 359 名国际成人 SMA 患者的横断面研究数据,我们确定了纳入 SMA-HI 的最相关症状。我们利用因子分析、成人和未成年人(8-15 岁)的患者访谈、已知组有效性测试以及测试-重测可靠性评估来评估和完善 SMA-HI。
SMA-HI 衡量整体疾病负担和 15 个 SMA 健康领域。15 名成年患者和 5 名 8 至 15 岁的患者参加了半结构化定性访谈,他们发现 SMA-HI 全面、易于完成且具有明确的含义。最终的 SMA-HI 及其子量表表现出良好的内部一致性(Cronbach α=0.77-0.96)、高测试-重测可靠性(组内相关系数=0.60-0.96),并且能够区分具有不同疾病严重程度的 SMA 群体,这些群体在就业和步行等方面存在差异(两者均 P<.0001)。
这项研究提供了证据,表明 SMA-HI 是一种有效的、相关的和可靠的结果测量工具,可用于评估年龄较大的儿童、青少年和成年 SMA 患者多方面的患者报告的疾病负担。SMA-HI 为研究人员和临床医生提供了一种衡量 SMA 患者对其健康的感知的机会,并确定了对治疗干预或疾病进展的相关变化。